Race and Ethnic Group Enrollment and Outcomes for Wilms Tumor: Analysis of the Current Era Children’s Oncology Group Study, AREN03B2

Author:

Lovvorn Harold N1,Renfro Lindsay A2,Benedetti Daniel J3,Kotagal Meera45,Phelps Hannah M6,Ehrlich Peter F7,Lo Andrea C8,Sandberg Jesse K9,Treece Amanda L10,Gow Kenneth W11,Glick Richard D12,Davidoff Andrew M13,Cost Nicholas G14,Dix David B15,Fernandez Conrad V16,Dome Jeffrey S17,Geller James I18,Mullen Elizabeth A19

Affiliation:

1. From the Department of Pediatric Surgery (Lovvorn)

2. Division of Biostatistics, University of Southern California, and Children’s Oncology Group, Los Angeles, CA (Renfro)

3. Division of Pediatric Hematology/Oncology, Department of Pediatrics (Benedetti), Monroe Carell Jr Children’s Hospital at Vanderbilt, Nashville, TN

4. Division of Pediatric General and Thoracic Surgery, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH (Kotagal)

5. Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH (Kotagal)

6. Department of Surgery, Washington University in St Louis School of Medicine, St Louis, MO (Phelps)

7. Section of Pediatric Surgery, C. S. Mott Children’s Hospital, University of Michigan, Ann Arbor, MI (Ehrlich)

8. Department of Radiation on Oncology, BC Cancer, Vancouver, British Columbia, Canada (Lo)

9. Division of Pediatric Radiology, Lucille Packard Children’s Hospital, Stanford University, Palo Alto, CA (Sandberg)

10. Department of Pathology and Laboratory Medicine, Children’s Hospital of Alabama, Birmingham, AL (Treece)

11. Division of General and Thoracic Surgery, Seattle Children’s Hospital, Seattle, WA (Gow)

12. Division of Pediatric Surgery, Cohen Children’s Medical Center, Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, NY (Glick)

13. Department of Surgery, St. Jude Children’s Research Hospital, Memphis, TN (Davidoff)

14. Division of Urology, Department of Surgery, University of Colorado School of Medicine, Surgical Oncology Program, Children’s Hospital Colorado, Aurora, CO (Cost)

15. Division of Hematology and Oncology, Department of Pediatrics, University of British Columbia, BC Children’s Hospital, Vancouver, British Columbia, Canada (Dix)

16. Division of Paediatric Haematology Oncology, Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia (Fernandez)

17. Center for Cancer and Blood Disorders, Children’s National Hospital, Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, DC (Dome)

18. Division of Oncology, Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH (Geller)

19. Division of Pediatric Hematology and Oncology, Dana-Farber Cancer Institute, Boston, MA (Mullen).

Abstract

BACKGROUND: To review race and ethnic group enrollment and outcomes for Wilms tumor (WT) across all 4 risk-assigned therapeutic trials from the current era Children’s Oncology Group Renal Tumor Biology and Risk Stratification Protocol, AREN03B2. STUDY DESIGN: For patients with WT enrolled in AREN03B2 (2006 to 2019), disease and biologic features, therapeutic study-specific enrollment, and event-free (EFS) and overall (OS) 4-year survival were compared between institutionally reported race and ethnic groups. RESULTS: Among 5,146 patients with WT, no statistically significant differences were detected between race and ethnic groups regarding subsequent risk-assigned therapeutic study enrollment, disease stage, histology, biologic factors, or overall EFS or OS, except the following variables: Black children were older and had larger tumors at enrollment, whereas Hispanic children had lower rates of diffuse anaplasia WT and loss of heterozygosity at 1p. The only significant difference in EFS or OS between race and ethnic groups was observed among the few children treated for diffuse anaplasia WT with regimen UH-1 and -2 on high-risk protocol, AREN0321. On this therapeutic arm only, Black children showed worse EFS (hazard ratio = 3.18) and OS (hazard ratio = 3.42). However, this finding was not replicated for patients treated with regimen UH-1 and -2 under AREN03B2 but not on AREN0321. CONCLUSIONS: Race and ethnic group enrollment appeared constant across AREN03B2 risk-assigned therapeutic trials. EFS and OS on these therapeutic trials when analyzed together were comparable regarding race and ethnicity. Black children may have experienced worse stage-specific survival when treated with regimen UH-1 and -2 on AREN0321, but this survival gap was not confirmed when analyzing additional high-risk AREN03B2 patients.

Publisher

Ovid Technologies (Wolters Kluwer Health)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3